<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transfus Med Rev</journal-id><journal-id journal-id-type="iso-abbrev">Transfus Med Rev</journal-id><journal-title-group><journal-title>Transfusion Medicine Reviews</journal-title></journal-title-group><issn pub-type="ppub">0887-7963</issn><issn pub-type="epub">1532-9496</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7127679</article-id><article-id pub-id-type="publisher-id">S0887-7963(19)30130-0</article-id><article-id pub-id-type="doi">10.1016/j.tmrv.2019.09.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Role of Complement in Transfusion-Related Acute Lung Injury</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Jongerius</surname><given-names>Ilse</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Porcelijn</surname><given-names>Leendert</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0015"><name><surname>van Beek</surname><given-names>Anna E.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0020"><name><surname>Semple</surname><given-names>John W.</given-names></name><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0025"><name><surname>van der Schoot</surname><given-names>C. Ellen</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0030"><name><surname>Vlaar</surname><given-names>Alexander P.J.</given-names></name><xref rid="af0030" ref-type="aff">f</xref><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0035"><name><surname>Kapur</surname><given-names>Rick</given-names></name><email>r.kapur@sanquin.nl</email><xref rid="af0025" ref-type="aff">e</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Sanquin Research, Department of Immunopathology, Amsterdam and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands</aff><aff id="af0010"><label>b</label>Emma Children's Hospital, Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Amsterdam UMC, Amsterdam, the Netherlands</aff><aff id="af0015"><label>c</label>Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, the Netherlands</aff><aff id="af0020"><label>d</label>Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden</aff><aff id="af0025"><label>e</label>Sanquin Research, Department of Experimental Immunohematology, Amsterdam and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands</aff><aff id="af0030"><label>f</label>Department of Intensive Care Medicine, Amsterdam UMC, AMC, Amsterdam, the Netherlands</aff><aff id="af0035"><label>g</label>Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Amsterdam UMC, AMC, Amsterdam, the Netherlands</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Rick Kapur, MD, PhD, MSc, Department of Experimental Immunohematology, Sanquin Research, Plesmanlaan 125, 1066 CX, Amsterdam, the Netherlands. <email>r.kapur@sanquin.nl</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>10</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>18</day><month>10</month><year>2019</year></pub-date><volume>33</volume><issue>4</issue><fpage>236</fpage><lpage>242</lpage><permissions><copyright-statement>&#x000a9; 2019 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>Transfusion-related acute lung injury (TRALI) is a life-threatening complication of acute respiratory distress occurring within 6 hours of blood transfusion. TRALI is one of the leading causes of transfusion-related fatalities and specific therapies are unavailable. Neutrophils are recognized as the major pathogenic cells, whereas T regulatory cells and dendritic cells appear to be important for protection against TRALI. The pathogenesis, however, is complex and incompletely understood. It is frequently postulated that the complement system plays an important role in the TRALI pathogenesis. In this article, we assess the evidence regarding the involvement of complement in TRALI from both human and animal studies. We hypothesize about the potential connection between the complement system and neutrophils in TRALI. Additionally, we draw parallels between TRALI and other acute pulmonary disorders of acute lung injury and acute respiratory distress syndrome regarding the involvement of complement. We conclude that, even though a role for complement in the TRALI pathogenesis seems plausible, studies investigating the role of complement in TRALI are remarkably limited in number and also present conflicting findings. Different types of TRALI animal models, diverse experimental conditions, and the composition of the gastrointestinal microbiota may perhaps all be factors which contribute to these discrepancies. More systematic studies are warranted to shed light on the contribution of the complement cascade in TRALI. The underlying clinical condition of the patient, which influences the susceptibility to TRALI, as well as the transfusion factor (antibody-mediated vs non&#x02013;antibody-mediated), will be important to take into consideration when researching the contribution of complement. This should significantly increase our understanding of the role of complement in TRALI and may potentially result in promising new treatment strategies.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>&#x02022;</label><p id="p0005">Studies investigating complement and TRALI are limited in number and present conflicting findings.</p></list-item><list-item id="li0010"><label>&#x02022;</label><p id="p0010">Systematic investigation is needed to better understand the contribution of the complement cascade in TRALI.</p></list-item><list-item id="li0015"><label>&#x02022;</label><p id="p0015">Future studies in this area should consider both the clinical susceptibility of the patient as well as the effect of transfusion factors.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Transfusion-related acute lung injury</kwd><kwd>TRALI</kwd><kwd>Complement</kwd><kwd>C5a</kwd><kwd>C5Ar</kwd><kwd>NETs</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1.1</label><title>Transfusion-Related Acute Lung Injury</title><p id="p0020">Transfusion-related acute lung injury (TRALI) is a syndrome of acute respiratory distress occurring within 6 hours of blood transfusion [<xref rid="bb0005" ref-type="bibr">1</xref>]. TRALI is characterized by the acute onset of noncardiogenic pulmonary edema [<xref rid="bb0005" ref-type="bibr">1</xref>]. It is one of the leading causes of transfusion-related fatalities, and specific therapies are lacking [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0010" ref-type="bibr">2</xref>]. TRALI is particularly prevalent in critically ill patients, with incidences reported up to 15% and with a reported survival rate as low as 53% compared to 83% in acute lung injury control patients [<xref rid="bb0015" ref-type="bibr">3</xref>].</p><p id="p0025">The pathogenesis of TRALI is complicated and incompletely understood [<xref rid="bb0005" ref-type="bibr">1</xref>]. Generally, a 2-hit model is considered to represent the TRALI pathophysiology [<xref rid="bb0020" ref-type="bibr">4</xref>,<xref rid="bb0025" ref-type="bibr">5</xref>]. The first hit is related to the underlying clinical condition of the patient (eg, inflammation), whereas the second hit is conveyed by factors in the transfused blood product. These second hit factors may be antibodies (around 60%-80% of all TRALI cases) such as anti&#x02013;human leukocyte antigen (HLA) class I or II or anti-human neutrophil antigen (HNA) antibodies [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0030" ref-type="bibr">6</xref>], or antibody-independent factors such as biological response modifiers (eg, lipids) [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0035" ref-type="bibr">7</xref>]. TRALI mainly occurs when both hits are combined, although cases have been described which report the onset of TRALI in healthy subjects (eg, [<xref rid="bb0040" ref-type="bibr">8</xref>]). Animal models of TRALI have significantly contributed to our current understanding of the pathophysiology [<xref rid="bb0045" ref-type="bibr">9</xref>]. Based on autopsy reports of TRALI patients, TRALI animal models, and in vitro TRALI experiments, neutrophils (PMNs) are considered to be the key pathogenic cells in antibody and non&#x02013;antibody-mediated TRALI (in the transfused recipient) [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>]. PMNs have been suggested to exert their pathogenic effects in TRALI through direct activation, production of reactive oxygen species (ROS), or the formation of neutrophil extracellular traps (NETs) [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>]. It was suggested, using a murine TRALI model, that anti&#x02013;major histocompatibility complex (MHC) class I antibodies may bind to the pulmonary endothelium and subsequently sequester PMNs via their Fc<italic>&#x003b3;</italic>Rs, resulting in PMN activation and TRALI induction [<xref rid="bb0055" ref-type="bibr">11</xref>]. In addition, using a murine model of anti-MHC class I antibody-mediated TRALI, PMNs and ROS were found to be critically required for TRALI induction as demonstrated by in vivo PMN depletion and by using C57BL/6 gp91phox knockout mice [<xref rid="bb0060" ref-type="bibr">12</xref>]. Furthermore, platelets were shown to induce NET formation in TRALI mice, suggesting that NETs may thereby induce lung injury via direct toxicity to pulmonary endothelial cells [<xref rid="bb0065" ref-type="bibr">13</xref>]. Additionally, NETs were shown to be formed upon direct priming of PMNs by anti-HNA-3a antibodies [<xref rid="bb0070" ref-type="bibr">14</xref>]. Regarding anti-HNA-3a&#x02013;mediated TRALI, PMNs were also demonstrated to interact with von Willebrand factor via CTL-2, the carrier of the HNA-3 antigen, which enabled antibody-induced signaling via CD11b/CD18, resulting in PMN activation and agglutination [<xref rid="bb0075" ref-type="bibr">15</xref>]. Next, monocytes/macrophages may exert pathogenic effects in TRALI [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0080" ref-type="bibr">16</xref>]. In addition, red blood cells (RBCs) from the transfusion product or from the transfused recipient have been suggested to elicit pathogenic effects in TRALI rat and mouse models [<xref rid="bb0005" ref-type="bibr">1</xref>]. Interestingly, targeting recipient red blood cells with the red blood specific antibody Ter119 was shown to prevent the occurrence of TRALI in a murine model [<xref rid="bb0085" ref-type="bibr">17</xref>]. On the other hand, CD4+ T regulatory cells [<xref rid="bb0060" ref-type="bibr">12</xref>,<xref rid="bb0090" ref-type="bibr">18</xref>] and dendritic cells [<xref rid="bb0060" ref-type="bibr">12</xref>] have been shown to be the major cells protecting against TRALI, as demonstrated using a murine model of TRALI. Much more research is required to understand the specific nature of the pathogenic immune responses occurring in TRALI. The complexity in dissecting the pathophysiology of TRALI is further illustrated by controversies which have arisen, such as the involvement of recipient platelets [<xref rid="bb0095" ref-type="bibr">19</xref>,<xref rid="bb0100" ref-type="bibr">20</xref>]. One of the other controversies appears to be the involvement of the complement system in TRALI, which will be the focus of the current article.</p></sec><sec id="s0010"><label>1.2</label><title>The Complement System</title><p id="p0030">The complement system forms an important part of the innate immune system. It eradicates microbial pathogens, apoptotic cells, and immune complexes while leaving healthy cells intact [<xref rid="bb0105" ref-type="bibr">21</xref>]. Activation of the complement system needs to be effectively controlled to prevent damage to the host, for which several complement regulatory proteins are present. During a blood transfusion, foreign blood cells enter the body, and in the presence of alloantibodies to antigenic polymorphisms on the recipient tissue, the complement system can be activated which can result in adverse transfusion reactions [<xref rid="bb0110" ref-type="bibr">22</xref>]. The complement system is composed of around 50 proteins which either reside in the blood or are membrane-bound. The complement system can be activated via three different routes, namely, the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP) [<xref rid="bb0105" ref-type="bibr">21</xref>]. Several diseases are linked to unwanted over-activation of the complement system. The CP is activated via allo- and autoantibodies bound to RBCs that are formed following RBC transfusion or present in autoimmune hemolytic anemia [<xref rid="bb0110" ref-type="bibr">22</xref>,<xref rid="bb0115" ref-type="bibr">23</xref>]. In addition, mutations resulting in altered function or lack of complement regulatory proteins are often associated with overactivation of the AP as seen in atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria [<xref rid="bb0120" ref-type="bibr">24</xref>,<xref rid="bb0125" ref-type="bibr">25</xref>]. In contrast to the CP and AP, however, diseases related to the LP are relatively poorly defined. Studies have indicated that inhibition of the LP might be therapeutically relevant in ischemia reperfusion injury, although the mechanism remains poorly understood [<xref rid="bb0130" ref-type="bibr">26</xref>,<xref rid="bb0135" ref-type="bibr">27</xref>]. Furthermore, a large part of the population is deficient in Mannose binding lectin (MBL), the key player in initiation of the LP, but when the MBL pathway is activated, the effects that occur are relatively mild and predominately result in (more) severe infections in neonates [<xref rid="bb0140" ref-type="bibr">28</xref>].</p><p id="p0035">Antibodies are the main drivers of the CP. Interestingly, complement was shown to be most effectively activated by IgG hexamers assembled at the cell surface [<xref rid="bb0145" ref-type="bibr">29</xref>]. In addition, the CP can also be activated via binding of C-reactive protein (CRP) to phosphocholine sites exposed on disrupted plasma membranes [<xref rid="bb0150" ref-type="bibr">[30]</xref>, <xref rid="bb0155" ref-type="bibr">[31]</xref>, <xref rid="bb0160" ref-type="bibr">[32]</xref>]. Binding of C1q to IgG, IgM, or CRP results in activation of C1s and C1r, which in turn cleave C4 and C2. The cleavage products, C4b and C2a, form the C3 convertase of the CP (C4b2a). The C3 convertase can cleave C3 into C3b and C3a. C3b covalently binds to the surface, whereas C3a is a chemoattractant for immune cells. Binding of C3b to the surface eventually leads to the formation of C5 convertases (C4b2aC3b) which cleave C5 and generate the potent chemoattractant C5a and the C5b which forms the basis of the membrane attack complex (MAC), which is composed of C5b-9.</p><p id="p0040">Activation of the LP occurs when carbohydrate moieties on microbial pathogens are bound by MBL or ficolins. This binding results in activation of the MBL-associated serine proteases (MASPs) which in turn cleave C4 and C2, forming a C3 convertase (C4b2a) analogous to activation via the CP [<xref rid="bb0105" ref-type="bibr">21</xref>]. The AP is an important player in the immune system, as it is believed that complement activation heavily relies on the amplification loop provided by the AP [<xref rid="bb0165" ref-type="bibr">33</xref>,<xref rid="bb0170" ref-type="bibr">34</xref>]. Although the AP can be initiated spontaneously at a low rate due to turnover of C3 into C3(H<sub>2</sub>O) in plasma, its main function lies in amplifying the C3b deposition on the (cellular) surface. When Factor B (FB) binds to a C3b molecule, it is cleaved by Factor D (FD), resulting in the formation of the AP C3 convertase C3bBb. This C3 convertase can also cleave C3, and incorporation of another C3b molecule results in formation of AP C5 convertases (C3bBbC3b) which, similar to CP/LP C5 convertases, results in C5 cleavage and generation of C5a and the MAC [<xref rid="bb0105" ref-type="bibr">21</xref>].</p><p id="p0045">Several fluid-phase and membrane-bound complement regulators inhibit the activation of the complement system. For example, the fluid phase regulators C1 inhibitor (C1-INH) and C4b binding protein (C4bp) inhibit activation via the CP and LP. On the other hand, the fluid-phase regulators Factor H (FH) and FH-like 1 (FHL-1) inhibit the AP [<xref rid="bb0175" ref-type="bibr">35</xref>]. In addition, the more recently discovered FH-related proteins (FHRs) are believed to fine tune the regulatory capacity of FH; however, in vivo evidence is lacking, and in vitro evidence is often contradicting [<xref rid="bb0180" ref-type="bibr">36</xref>]. Most cells express several membrane-bound regulators like complement receptor (CR) 1, CD46 (also known as <italic>membrane cofactor protein</italic> [MCP]), CD55 (also known as <italic>decay-accelerating factor</italic> (DAF), and CD59. Finally, the fluid phase regulators vitronectin and clusterin are able to prevent formation of the MAC, whereas Factor I (FI) is a glycoprotein that downregulates the complement system by cleavage of deposited C4b and C3b into inactive forms C3d and C4d in the presence of co-factors such as FH, C4bp, CR1, and MCP [<xref rid="bb0175" ref-type="bibr">35</xref>]. The complement system is schematically summarized in <xref rid="f0005" ref-type="fig">Figure 1</xref>A.<fig id="f0005"><label>Fig 1</label><caption><p>A, The complement system. The complement system is initiated by the binding of recognition molecules from the lectin or the classical pathway (LP and CP). In the LP, MBL or ficolins (Fic) are complexed with MASP proteins and recognize glycan moieties on a pathogenic surface. The C1 complex, composed of C1q and 2 molecules of C1r and C1s each, recognizes antibody-antigen complexes. After activation of the MASP proteins or C1r/C1s, C4 is cleaved by C1s into C4b, which deposits on the surface via its thioester. The subsequent cleavage of C2 by C1s allows for the formation of the C4b2a C3 convertase&#x02014;able to cleave C3 into C3b. Via the AP, a C3 convertase, can also form in the fluid phase, composed of C3(H<sub>2</sub>O) and Bb (the large product upon FB cleavage by FD), or as C3bBb deposited on the surface. Both these AP convertases are stabilized with properdin (P). The alternative pathway functions as an amplification loop, increasing the deposition of C3b. When the number of deposited C3b molecules increases, C5 becomes the preferred substrate for the convertases, initiating the terminal pathway. C5b, together with C6, C7, C8, and several molecules of C9, forms a lytic pore known as the <italic>membrane-attack complex</italic> (MAC).</p><p>B, The breakdown of deposited C3b. C3b that is attached to a surface can be regulated via multiple mechanisms. FH, DAF (CD55), and complement receptor 1 (CR1) are able to compete with FB to prevent formation or accelerate the decay of the AP C3 convertase. In addition, FH, MCP (CD46), and CR1 function as cofactors for the serine protease FI to cleave C3b into its inactive form, iC3b, releasing the C3f fragment. CR1 also aids FI to cleave iC3b into C3dg. Other plasma proteases will cleave off the last C3g fragment, leaving the last antigenic fragment, C3d, attached to the surface.</p></caption><alt-text id="al0005">Fig 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0050">As TRALI is frequently triggered by antibodies present in the transfusion product [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0030" ref-type="bibr">6</xref>] and CRP also plays an important pathogenic role in TRALI [<xref rid="bb0185" ref-type="bibr">37</xref>] and is increased in TRALI patients [<xref rid="bb0190" ref-type="bibr">38</xref>], the involvement of complement, and specifically the CP, in TRALI appears to be plausible.</p></sec><sec id="s0015"><label>2</label><title>Evidence for the Involvement of Complement in TRALI</title><p id="p0055">Although it has been suggested that the complement system plays a role in TRALI, the number of studies directly investigating this appears to be surprisingly limited. Regarding human studies, Ambruso et al reported (published abstract only) the activation of complement in 2 anti-HLA class II-mediated TRALI patient samples, which was absent in pretransfusion samples [<xref rid="bb0195" ref-type="bibr">39</xref>]. Interestingly, the authors found complement to be activated in the product transfused during the onset of TRALI symptoms, suggesting that the activated complement components in the transfusion product played a role in the TRALI reaction. In a prospective, randomized, double-blind, crossover study, Palfi et al looked into the C3d concentrations in pre- and posttransfusion plasma samples of intensive care patients receiving plasma from multiparous donors compared to those receiving plasma from nontransfused nulliparous women [<xref rid="bb0200" ref-type="bibr">40</xref>]. C3d results from the breakdown of deposited C3b (<xref rid="f0005" ref-type="fig">Fig 1</xref>B). It was concluded that plasma from multiparous blood donors may impair pulmonary function in intensive care unit patients, but the authors did not find any differences in C3d levels. Notably, however, only 5 posttransfusion reactions occurred (in 4 cases after the transfusion of plasma from multiparous donors) in 100 patients, of which there were 1 typical TRALI reaction and 4 mild cases of TRALI. Lucas et al found complement fixing anti-HNA-1a IgM antibodies in the serum of 1 female donor (out of the 3 donors of the pooled platelet concentrate) that may have triggered TRALI due to interdonor incompatibility for HNA-1a [<xref rid="bb0205" ref-type="bibr">41</xref>]. Dry et al performed an autopsy of a TRALI patient and did not observe the presence of macrophages in the alveolar air spaces [<xref rid="bb0210" ref-type="bibr">42</xref>], which has been described to occur 24-48 hours after infusion of activated complement in rabbit lungs [<xref rid="bb0215" ref-type="bibr">43</xref>]. This lack of intra-alveolar macrophages, however, may not yet have occurred because the TRALI patient died 2 hours after initial clinical signs of pulmonary edema.</p><p id="p0060">Studies using animal models of TRALI have also assessed a contribution of (components of) the complement system. M&#x000fc;ller and colleagues used a murine model of TRALI based on lipopolysaccharide (LPS) priming and infusion of an anti-MHC class I antibody [<xref rid="bb0220" ref-type="bibr">44</xref>]. This resulted in increased levels of C3a and C5a in bronchoalveolar lavage fluid (BALF). C1-INH attenuated the pulmonary levels of C3a associated with improved lung injury scores; however, there was no effect on C5a levels in the BALF. In addition, despite the administration of the C1-INH, high levels of pulmonary and systemic inflammatory cytokines persisted, including macrophage inflammatory protein (MIP)-2, the murine homolog of IL-8. Furthermore, Strait and colleagues found an important role for C5a in murine TRALI using the anti-MHC class I antibody (34-1-2s) in BALB/c mice [<xref rid="bb0225" ref-type="bibr">45</xref>]. Mice which were deficient in C3, C5, or C5a receptor (C5aR) were protected from TRALI. The requirement for C5a for TRALI induction was suggested to be related to the fact that only adult male mice were susceptible to 34-1-2s&#x02013;mediated TRALI, whereas adult female mice were apparently resistant [<xref rid="bb0225" ref-type="bibr">45</xref>]. Female mice have only approximately 25% as much plasma C5 as males, and the subtype of C5 in male mice is not present in females, which may at least in part explain these sex-specific differences in TRALI susceptibility [<xref rid="bb0230" ref-type="bibr">46</xref>]. This was further supported by data demonstrating that infusion of female mice with plasma from male WT or male C3-deficient mice enabled TRALI, whereas infusion with plasma from C5-deficient males failed to induce TRALI [<xref rid="bb0225" ref-type="bibr">45</xref>]. Looney and coworkers, on the other hand, described the occurrence of TRALI in C5aR-deficient BALB/c mice 2 hours after TRALI induction with 34-1-2s injection, suggesting C5a to be dispensable in murine TRALI [<xref rid="bb0055" ref-type="bibr">11</xref>]. Differences between the study of Strait et al [<xref rid="bb0225" ref-type="bibr">45</xref>] and Looney et al [<xref rid="bb0055" ref-type="bibr">11</xref>] may be explained by the timing of experimental endpoints after 34-1-2s injection, which was 30 minutes in the study by Strait et al [<xref rid="bb0225" ref-type="bibr">45</xref>], whereas this was 2 hours in the study of Looney et al [<xref rid="bb0055" ref-type="bibr">11</xref>]. Additionally, the observed differences may be due to the nature of the animal housing which may affect the composition of the gastrointestinal microbiota and thereby the susceptibility to TRALI [<xref rid="bb0095" ref-type="bibr">19</xref>,<xref rid="bb0235" ref-type="bibr">47</xref>]. Furthermore, in a study by Sachs et al using an ex vivo rat model of anti-CD177&#x02013;mediated TRALI, complement was not found to be required for TRALI induction (TRALI induction was more dependent on the density of the cognate antigen), as TRALI occurred in a complement-free environment [<xref rid="bb0240" ref-type="bibr">48</xref>]. In an earlier ex vivo TRALI study by Seeger and colleagues using rabbit lungs, rabbit plasma was suggested to have served as a source of complement and induced TRALI together with anti-5b (anti-HNA-3a) antibodies and PMNs [<xref rid="bb0245" ref-type="bibr">49</xref>]. In this study, however, there was no direct investigation regarding the contribution of complement.</p><p id="p0065">All the studies mentioned above, which provide evidence supporting or against the involvement of complement in TRALI, are summarized in <xref rid="t0005" ref-type="table">Table 1</xref>
.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Evidence supporting or against the involvement of complement in TRALI</p></caption><alt-text id="al0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Animal/human</th><th>Evidence supporting complement involvement in TRALI</th><th>Evidence against complement involvement in TRALI</th></tr></thead><tbody><tr><td>Ambruso et al, <italic>Blood</italic> 2006 (abstract) [<xref rid="bb0195" ref-type="bibr">39</xref>]</td><td>Human</td><td>Complement activation was observed in 2 patient samples during the anti-HLA class II&#x02013;mediated TRALI reaction as opposed to those patient samples collected before the transfusion. Complement was activated in the product transfused during the onset of TRALI symptoms.</td><td/></tr><tr><td>Palfi et al, <italic>Transfusion</italic> 2001 [<xref rid="bb0200" ref-type="bibr">40</xref>]</td><td>Human</td><td/><td>No difference in C3d concentrations in pre- and posttransfusion plasma samples of intensive care patients receiving plasma from multiparous donors compared to those receiving plasma from donors with no history of transfusion or pregnancy in a prospective, randomized, double-blind, crossover study in which 5 posttransfusion reactions occurred.</td></tr><tr><td>Lucas et al, <italic>Vox Sang</italic> 2000 [<xref rid="bb0205" ref-type="bibr">41</xref>]</td><td>Human</td><td>Complement fixing anti-HNA-1a IgM antibodies in sera of 1 female donor (out of the 3 donors of the pooled platelet concentrate) initiated a TRALI reaction due to interdonor incompatibility for HNA-1a.</td><td/></tr><tr><td>Dry et al, <italic>Am J Clin Pathol</italic> 1999 [<xref rid="bb0210" ref-type="bibr">42</xref>]</td><td>Human</td><td/><td>Autopsy of TRALI patient did not demonstrate the presence of macrophages within alveolar air spaces as has been described to occur 24 to 48 h after activated complement infusion in rabbit lungs [<xref rid="bb0210" ref-type="bibr">42</xref>].</td></tr><tr><td>M&#x000fc;ller, <italic>Vox Sang</italic> 2014 [<xref rid="bb0220" ref-type="bibr">44</xref>]</td><td>Mouse</td><td>Increased C3a and C5a in BALF upon LPS priming and anti-MHC class I antibody-mediated TRALI induction in mice. C1-inhibitor attenuated pulmonary levels of C3a associated with improved lung injury scores.</td><td>No effect on C5a levels in BALF plus persistence of high levels of pulmonary and systemic inflammatory cytokines (including MIP-2) with C1-inhibitor (C1-INH).</td></tr><tr><td>Strait et al, <italic>J Exp Med</italic> 2011 [<xref rid="bb0225" ref-type="bibr">45</xref>]</td><td>Mouse</td><td>C5a in particular was found to be important in inducing anti-MHC class I antibody (34-1-2s)&#x02013;mediated murine TRALI. Mice deficient in C3, C5, or C5a receptor (C5aR) did not develop any TRALI 30 min after TRALI induction.</td><td/></tr><tr><td>Looney et al, <italic>J Clin Invest</italic> 2006 [<xref rid="bb0055" ref-type="bibr">11</xref>]</td><td>Mouse</td><td/><td>Occurrence of TRALI in C5aR-deficient BALB/c mice 2 h after 34-1-2s injection.</td></tr><tr><td>Sachs et al, <italic>Blood</italic> 2006 [<xref rid="bb0240" ref-type="bibr">48</xref>]</td><td>Rat</td><td/><td>Complement was not found to be required for TRALI induction in an ex vivo rat lung model, where TRALI induction by CD177-specific antibodies was found to occur in a complement-free environment.</td></tr><tr><td>Seeger et al, <italic>Blood</italic> 1990 [<xref rid="bb0245" ref-type="bibr">49</xref>]</td><td>Rabbit</td><td>Rabbit plasma may have served as a source of complement and induced severe lung edema and increased lung vascular permeability in an ex vivo rabbit lung model together with anti-5b (anti-HNA-3a) antibodies and PMNs.</td><td/></tr></tbody></table></table-wrap></p></sec><sec id="s0020"><label>3</label><title>The Potential Connection Between the Complement System and PMNs in Immune Disorders</title><p id="p0070">PMNs are the key pathogenic cells in TRALI, exerting their effects through direct activation, ROS production, or release of NETs [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>]. Interestingly, the innate immune system is able to activate PMNs via different effector molecules. IgG bound to its target is recognized by PMNs via their Fc<italic>&#x003b3;</italic> receptors (Fc<italic>&#x003b3;</italic>Rs) [<xref rid="bb0250" ref-type="bibr">50</xref>,<xref rid="bb0255" ref-type="bibr">51</xref>]. C3b and its degradation products can be recognized by several CRs, and C3a and C5a, which are generated during complement activation, are potent chemoattractants [<xref rid="bb0105" ref-type="bibr">21</xref>,<xref rid="bb0260" ref-type="bibr">52</xref>]. Recognition of these substrates results in PMN activation, ROS production, and NET formation [<xref rid="bb0250" ref-type="bibr">50</xref>,<xref rid="bb0255" ref-type="bibr">51</xref>,<xref rid="bb0265" ref-type="bibr">53</xref>].</p><p id="p0075">Immune complexes are capable of binding to activating and inhibitory Fc<italic>&#x003b3;</italic>Rs which are expressed by innate immune effector cells including PMNs [<xref rid="bb0270" ref-type="bibr">54</xref>]. The ROS response mediated by IgG is influenced by the combination of Fc<italic>&#x003b3;</italic>RIIa and Fc<italic>&#x003b3;</italic>RIIIb isoforms expressed on PMNs [<xref rid="bb0275" ref-type="bibr">55</xref>]. PMNs that are activated by IgG elicit a robust ROS response [<xref rid="bb0280" ref-type="bibr">56</xref>]. It has been shown that blocking of PMN-Fc<italic>&#x003b3;</italic>RIIIb is sufficient to inhibit immune complex&#x02013; mediated ROS production in a setting of autoimmune arthritis [<xref rid="bb0285" ref-type="bibr">57</xref>]. Next to activation via immune complexes, ROS production in PMNs can also occur after activation with C5a [<xref rid="bb0105" ref-type="bibr">21</xref>,<xref rid="bb0290" ref-type="bibr">58</xref>]. Furthermore, the importance of blocking C5a and the C5aR in complement-mediated PMN activation and ROS production is also shown in an in vivo anti-neutrophil cytoplasmic autoantibody model of glomerulonephritis, which suggests that the C5a receptor mediates PMN activation and ROS formation in anti-neutrophil cytoplasmic autoantibody&#x02013;induced glomerulonephritis [<xref rid="bb0295" ref-type="bibr">59</xref>]. Importantly, it has been shown that production of ROS is of high importance to induce NETs [<xref rid="bb0300" ref-type="bibr">60</xref>].</p><p id="p0080">Several autoimmune diseases are characterized by the presence of immune complexes, and in vivo and in vitro studies have shown that immune complexes can induce the release of NETs via binding to Fc<italic>&#x003b3;</italic>Rs [<xref rid="bb0305" ref-type="bibr">61</xref>,<xref rid="bb0310" ref-type="bibr">62</xref>]. In addition, these immune complexes can activate the complement system via the CP. The importance of C3 in NET formation was first shown in mice where it was found that PMNs of C3-deficient mice did not form NETs [<xref rid="bb0315" ref-type="bibr">63</xref>]. Also, Guglietta et al reported C3aR-dependent NET formation in a setting of small intestinal tumorigenesis [<xref rid="bb0320" ref-type="bibr">64</xref>]. In that study, circulating LPS was found to upregulate C3aRs on PMNs resulting in C3aR-dependent NET formation, induction of coagulation, and stimulation of protumorigenic neutrophilia. In addition, it was shown that pathogens that were opsonized with both IgG and C3b induced more NET formation than bacteria opsonized with IgG alone [<xref rid="bb0325" ref-type="bibr">65</xref>]. Furthermore, it is not only C3 that is involved in the release of NETs because NET induction by antibodies and immune complexes is greatly enhanced when PMNs are first primed by C5a [<xref rid="bb0330" ref-type="bibr">66</xref>,<xref rid="bb0335" ref-type="bibr">67</xref>].</p><p id="p0085">In addition, studies have shown the link between activation of Fc<italic>&#x003b3;</italic>Rs and the C5aR [<xref rid="bb0255" ref-type="bibr">51</xref>,<xref rid="bb0340" ref-type="bibr">68</xref>]. For instance, using the K/BxN mouse serum transfer-induced arthritis mouse model expressing human Fc<italic>&#x003b3;</italic>RIIa on PMNs but lacking their own activating Fc<italic>&#x003b3;</italic>R (&#x003b3;-chain&#x02013;deficient mice), it was shown that cross talk between PMN-Fc<italic>&#x003b3;</italic>RIIa and PMN-C5aR promoted inflammatory arthritis in mice [<xref rid="bb0340" ref-type="bibr">68</xref>].</p><p id="p0090">Taken together, the complement system is a potent system to activate PMNs, and induce ROS production and NET formation, all processes also described to occur in TRALI [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>].</p></sec><sec id="s0025"><label>4</label><title>Complement Involvement in Acute Lung Injury and ARDS</title><p id="p0095">In further assessment of the potential contribution of complement in TRALI, parallels may be drawn with other forms of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).</p><p id="p0100">Activation of the complement system plays an important role in ALI caused by highly pathogenic viruses such as influenza virus A (H5N1 and H7N9) and severe acute respiratory syndrome [<xref rid="bb0345" ref-type="bibr">69</xref>]. It has been shown that infection of the human host with highly pathogenic viruses such as influenza A results in complement activation and formation of C5a [<xref rid="bb0345" ref-type="bibr">69</xref>,<xref rid="bb0350" ref-type="bibr">70</xref>]. In addition, BALF and serum of mice and humans infected with fatal H1N1 virus contained increased levels of C5a [<xref rid="bb0355" ref-type="bibr">71</xref>,<xref rid="bb0360" ref-type="bibr">72</xref>]. Furthermore, it has been shown that ALI induced by H5N1 played a relevant role by excessive complement activation including C5a generation [<xref rid="bb0365" ref-type="bibr">73</xref>]. Several murine in vivo studies using H1N1 and H5N1 as ALI inducers have shown beneficial effects of blocking C5a or C5aR in ALI [<xref rid="bb0345" ref-type="bibr">69</xref>,<xref rid="bb0360" ref-type="bibr">[72]</xref>, <xref rid="bb0365" ref-type="bibr">[73]</xref>, <xref rid="bb0370" ref-type="bibr">[74]</xref>, <xref rid="bb0375" ref-type="bibr">[75]</xref>]. In addition, C5a can also directly impact vascular permeability by activating endothelial cells [<xref rid="bb0110" ref-type="bibr">22</xref>], which are also activated in TRALI [<xref rid="bb0380" ref-type="bibr">76</xref>]. Russkamp et al observed alveolar inflammation with increased recruitment of Ly6-G(+)CD11b(+) leukocytes to the alveolar air spaces with severe alveolar-capillary barrier dysfunction upon intratracheal administration of C5a in mice [<xref rid="bb0370" ref-type="bibr">74</xref>]. The authors demonstrated a role for the CC-chemokine receptor 5 in their model of C5a-mediated ALI. Furthermore, as discussed above, C5a plays an important role in ROS generation and formation of NETs. Similar to TRALI, ROS and NETs have also been shown to play a role in ALI [<xref rid="bb0345" ref-type="bibr">69</xref>,<xref rid="bb0385" ref-type="bibr">[77]</xref>, <xref rid="bb0390" ref-type="bibr">[78]</xref>, <xref rid="bb0395" ref-type="bibr">[79]</xref>]. Notably, it was suggested that intravascular activation of PMNs by C5a may be related to the generation of ROS, resulting in the onset of ALI [<xref rid="bb0390" ref-type="bibr">78</xref>]. These studies underline the importance of C5a in mediating ALI and may support further investigations into the role of C5a in TRALI.</p><p id="p0105">ARDS is a serious and frequent complication of multiple medical and surgical interventions, with pneumonia, sepsis, and aspiration of gastric contents being common risk factors, and like TRALI, PMNs appear to play a strong role in the pathogenesis of ARDS [<xref rid="bb0050" ref-type="bibr">10</xref>]. ARDS occurs within 1 week of a known clinical insult or presents with new/worsening respiratory symptoms in case of an unknown clinical event. The role of the complement system in ARDS is not extensively studied. C5a was not detectable in 38 polytrauma patients at risk to develop ARDS, but monitoring of C3a and C3 in plasma was suggested to identify polytrauma patients at high risk for ARDS at an early stage of the disease [<xref rid="bb0400" ref-type="bibr">80</xref>]. In contrast, a different study of 61 patients at risk for ARDS development, due to a major nonthoracic trauma or fungemia, gram-negative bacteremia, or hypotension lasting more than 2 hours, found C5a to be a useful predictor for ARDS [<xref rid="bb0405" ref-type="bibr">81</xref>]. Yet, another study by Schein and colleagues investigated 59 patients in septic shock and found no indicative effect of complement activation whatsoever for the development of ARDS [<xref rid="bb0410" ref-type="bibr">82</xref>]. The discrepancy between these studies may be related to the different ARDS etiologies. It appears that the complement system may perhaps play a role in ARDS, but the heterogeneous etiologies of ARDS add to the complexity and should be carefully considered when studying the exact role of the different complement proteins in various types of ARDS. This may also be true for assessing the role of complement in TRALI, as the underlying clinical condition of the patient also influences the susceptibility to TRALI. Additionally, the transfusion factor (antibody-mediated vs non&#x02013;antibody-mediated) should be taken into account.</p></sec><sec id="s0030"><label>5</label><title>Conclusions</title><p id="p0110">It is frequently assumed that the complement system is part of the TRALI pathogenesis, which hypothetically seems plausible as outlined in this article. Studies systematically investigating the role of complement in TRALI, however, appear to be surprisingly limited in number. Moreover, the reported studies demonstrate conflicting data regarding complement involvement in TRALI. This apparent controversy may at least in part be explained by the different types of TRALI animal models and the varying experimental conditions. This may possibly include the manufacturing process used to generate the 34-1-2s antibody, which may have differed between studies, and this may consequently have differentially impacted the antibody-Fc glycosylation composition and thereby the interaction with Fc receptors or complement. Additionally, the controversy may possibly be due to the composition of the gastrointestinal microbiota [<xref rid="bb0235" ref-type="bibr">47</xref>], which can be influenced by changes in environmental animal housing conditions (specific pathogen-free vs barrier-free housing) [<xref rid="bb0095" ref-type="bibr">19</xref>,<xref rid="bb0235" ref-type="bibr">47</xref>]. Barrier-free mice were shown to be hypersusceptible to TRALI, whereas specific pathogen-free mice were resistant to TRALI (unless primed with LPS), and fecal transfer from barrier-free mice to specific pathogen-free mice could restore the susceptibility to TRALI [<xref rid="bb0235" ref-type="bibr">47</xref>], indicating a role for the gastrointestinal microbiota in TRALI. Overall, this reveals a need for systematic in-depth investigations into the potential contribution of various complement cascade components in inducing TRALI. This can be performed using both TRALI animal models (including the use of complement component knockout mice and the testing of available specific complement cascade inhibitors) as well as TRALI patient samples. The underlying clinical condition of the patient, which influences the susceptibility to TRALI, as well as the transfusion factor (antibodies vs biological response modifiers) should be taken into account (the latter has not been investigated). This will shed light on the relevance of the complement system in TRALI which may open up new therapeutic avenues to explore in combatting TRALI; for example, eculizumab, an anti-C5 blocking antibody or anti-FH.07 antibody which targets FH, or C1-INH.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>JW</given-names></name><name><surname>Rebetz</surname><given-names>J</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name></person-group><article-title>Transfusion-associated circulatory overload and transfusion-related acute lung injury</article-title><source>Blood</source><volume>133</volume><year>2019</year><fpage>1840</fpage><lpage>1853</lpage><pub-id pub-id-type="pmid">30808638</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>JW</given-names></name><name><surname>McVey</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Rebetz</surname><given-names>J</given-names></name><name><surname>Kuebler</surname><given-names>WM</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name></person-group><article-title>Targeting transfusion-related acute lung injury: the journey from basic science to novel therapies</article-title><source>Crit Care Med</source><volume>46</volume><year>2018</year><fpage>e452</fpage><lpage>e458</lpage><pub-id pub-id-type="pmid">29384784</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Vlaar</surname><given-names>AP</given-names></name><name><surname>Binnekade</surname><given-names>JM</given-names></name><name><surname>Prins</surname><given-names>D</given-names></name><name><surname>Van Stein</surname><given-names>D</given-names></name><name><surname>Hofstra</surname><given-names>JJ</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name></person-group><article-title>Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study</article-title><source>Crit Care Med</source><volume>38</volume><year>2010</year><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">20035217</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Silliman</surname><given-names>CC</given-names></name><name><surname>Paterson</surname><given-names>AJ</given-names></name><name><surname>Dickey</surname><given-names>WO</given-names></name><name><surname>Stroneck</surname><given-names>DF</given-names></name><name><surname>Popovsky</surname><given-names>MA</given-names></name><name><surname>Caldwell</surname><given-names>SA</given-names></name></person-group><article-title>The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study</article-title><source>Transfusion</source><volume>37</volume><year>1997</year><fpage>719</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">9225936</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Silliman</surname><given-names>CC</given-names></name></person-group><article-title>The two-event model of transfusion-related acute lung injury</article-title><source>Crit Care Med</source><volume>34</volume><year>2006</year><fpage>S124</fpage><lpage>S131</lpage><pub-id pub-id-type="pmid">16617256</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>AL</given-names></name><name><surname>Van</surname><given-names>SD</given-names></name><name><surname>Vlaar</surname><given-names>AP</given-names></name></person-group><article-title>Antibody-mediated transfusion-related acute lung injury; from discovery to prevention</article-title><source>Br J Haematol</source><volume>170</volume><year>2015</year><fpage>597</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">25921271</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>AL</given-names></name><name><surname>van Hezel</surname><given-names>ME</given-names></name><name><surname>Juffermans</surname><given-names>NP</given-names></name><name><surname>Vlaar</surname><given-names>AP</given-names></name></person-group><article-title>Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside</article-title><source>Blood Rev</source><volume>29</volume><year>2015</year><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">25277811</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Dooren</surname><given-names>MC</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>Verhoeven</surname><given-names>AJ</given-names></name><name><surname>von dem Borne</surname><given-names>AE</given-names></name><name><surname>Kuijpers</surname><given-names>RW</given-names></name></person-group><article-title>Adult respiratory distress syndrome after experimental intravenous gamma-globulin concentrate and monocyte-reactive IgG antibodies</article-title><source>Lancet</source><volume>352</volume><year>1998</year><fpage>1601</fpage><lpage>1602</lpage><pub-id pub-id-type="pmid">9843115</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><mixed-citation publication-type="other" id="or0005">Fung,Y.L and Tung, J.P. How different animal models help us understand TRALI. ISBT Sci Ser 2018;13:197-205.</mixed-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Rebetz</surname><given-names>J</given-names></name><name><surname>Semple</surname><given-names>JW</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name></person-group><article-title>The pathogenic involvement of neutrophils in acute respiratory distress syndrome and transfusion-related acute lung injury</article-title><source>Transfus Med Hemother</source><volume>45</volume><year>2018</year><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">30498407</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Looney</surname><given-names>MR</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Van Ziffle</surname><given-names>JA</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury</article-title><source>J Clin Invest</source><volume>116</volume><year>2006</year><fpage>1615</fpage><lpage>1623</lpage><pub-id pub-id-type="pmid">16710475</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Aslam</surname><given-names>R</given-names></name><name><surname>McVey</surname><given-names>MJ</given-names></name><name><surname>Tabuchi</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>A</given-names></name></person-group><article-title>T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10</article-title><source>Blood</source><volume>129</volume><year>2017</year><fpage>2557</fpage><lpage>2569</lpage><pub-id pub-id-type="pmid">28202460</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Caudrillier</surname><given-names>A</given-names></name><name><surname>Kessenbrock</surname><given-names>K</given-names></name><name><surname>Gilliss</surname><given-names>BM</given-names></name><name><surname>Nguyen</surname><given-names>JX</given-names></name><name><surname>Marques</surname><given-names>MB</given-names></name><name><surname>Monestier</surname><given-names>M</given-names></name></person-group><article-title>Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury</article-title><source>J Clin Invest</source><volume>122</volume><year>2012</year><fpage>2661</fpage><lpage>2671</lpage><pub-id pub-id-type="pmid">22684106</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>GM</given-names></name><name><surname>Carbo</surname><given-names>C</given-names></name><name><surname>Curtis</surname><given-names>BR</given-names></name><name><surname>Martinod</surname><given-names>K</given-names></name><name><surname>Mazo</surname><given-names>IB</given-names></name><name><surname>Schatzberg</surname><given-names>D</given-names></name></person-group><article-title>Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice</article-title><source>Blood</source><volume>119</volume><year>2012</year><fpage>6335</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">22596262</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Bayat</surname><given-names>B</given-names></name><name><surname>Tjahjono</surname><given-names>Y</given-names></name><name><surname>Berghofer</surname><given-names>H</given-names></name><name><surname>Werth</surname><given-names>S</given-names></name><name><surname>Deckmyn</surname><given-names>H</given-names></name><name><surname>De Meyer</surname><given-names>SF</given-names></name></person-group><article-title>Choline transporter-like protein-2: new von Willebrand Factor-binding partner involved in antibody-mediated neutrophil activation and transfusion-related acute lung injury</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>35</volume><year>2015</year><fpage>1616</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">25931511</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Kasetty</surname><given-names>G</given-names></name><name><surname>Rebetz</surname><given-names>J</given-names></name><name><surname>Egesten</surname><given-names>A</given-names></name><name><surname>Semple</surname><given-names>JW</given-names></name></person-group><article-title>Osteopontin mediates murine transfusion-related acute lung injury via stimulation of pulmonary neutrophil accumulation</article-title><source>Blood</source><volume>134</volume><issue>1</issue><year>2019</year><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">31076444</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Crow</surname><given-names>AR</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Koernig</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>IK</given-names></name><name><surname>Jen</surname><given-names>CC</given-names></name><name><surname>Mott</surname><given-names>PJ</given-names></name></person-group><article-title>Treating murine inflammatory diseases with an anti-erythrocyte antibody</article-title><source>Sci Transl Med</source><volume>11</volume><year>2019</year></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>He</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>P</given-names></name></person-group><article-title>Preventing murine transfusion-related acute lung injury by expansion of CD4(+) CD25(+) FoxP3(+) Tregs using IL-2/anti-IL-2 complexes</article-title><source>Transfusion</source><volume>59</volume><year>2019</year><fpage>534</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">30499590</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Looney</surname><given-names>MR</given-names></name><name><surname>Nguyen</surname><given-names>JX</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Van Ziffle</surname><given-names>JA</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury</article-title><source>J Clin Invest</source><volume>119</volume><year>2009</year><fpage>3450</fpage><lpage>3461</lpage><pub-id pub-id-type="pmid">19809160</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Hechler</surname><given-names>B</given-names></name><name><surname>Maitre</surname><given-names>B</given-names></name><name><surname>Magnenat</surname><given-names>S</given-names></name><name><surname>Heim</surname><given-names>V</given-names></name><name><surname>El Mdawar</surname><given-names>MB</given-names></name><name><surname>Gachet</surname><given-names>C</given-names></name></person-group><article-title>Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse</article-title><source>J Thromb Haemost</source><volume>14</volume><year>2016</year><fpage>1255</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">27063192</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Merle</surname><given-names>NS</given-names></name><name><surname>Church</surname><given-names>SE</given-names></name><name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name><name><surname>Roumenina</surname><given-names>LT</given-names></name></person-group><article-title>Complement system part I&#x02014;molecular mechanisms of activation and regulation</article-title><source>Front Immunol</source><volume>6</volume><year>2015</year><fpage>262</fpage><pub-id pub-id-type="pmid">26082779</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Stowell</surname><given-names>SR</given-names></name><name><surname>Winkler</surname><given-names>AM</given-names></name><name><surname>Maier</surname><given-names>CL</given-names></name><name><surname>Arthur</surname><given-names>CM</given-names></name><name><surname>Smith</surname><given-names>NH</given-names></name><name><surname>Girard-Pierce</surname><given-names>KR</given-names></name></person-group><article-title>Initiation and regulation of complement during hemolytic transfusion reactions</article-title><source>Clin Dev Immunol</source><volume>2012</volume><year>2012</year><object-id pub-id-type="publisher-id">307093</object-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Berentsen</surname><given-names>S</given-names></name></person-group><article-title>Role of complement in autoimmune hemolytic anemia</article-title><source>Transfus Med Hemother</source><volume>42</volume><year>2015</year><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">26696798</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Parente</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>SJ</given-names></name><name><surname>Inforzato</surname><given-names>A</given-names></name><name><surname>Day</surname><given-names>AJ</given-names></name></person-group><article-title>Complement factor H in host defense and immune evasion</article-title><source>Cell Mol Life Sci</source><volume>74</volume><year>2017</year><fpage>1605</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">27942748</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>DeZern</surname><given-names>AE</given-names></name><name><surname>Brodsky</surname><given-names>RA</given-names></name></person-group><article-title>Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia</article-title><source>Hematol Oncol Clin North Am</source><volume>29</volume><year>2015</year><fpage>479</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">26043387</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Schwaeble</surname><given-names>WJ</given-names></name><name><surname>Lynch</surname><given-names>NJ</given-names></name><name><surname>Clark</surname><given-names>JE</given-names></name><name><surname>Marber</surname><given-names>M</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Ali</surname><given-names>YM</given-names></name></person-group><article-title>Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury</article-title><source>Proc Natl Acad Sci U S A</source><volume>108</volume><year>2011</year><fpage>7523</fpage><lpage>7528</lpage><pub-id pub-id-type="pmid">21502512</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Dobo</surname><given-names>J</given-names></name><name><surname>Kocsis</surname><given-names>A</given-names></name><name><surname>Gal</surname><given-names>P</given-names></name></person-group><article-title>Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1851</fpage><pub-id pub-id-type="pmid">30135690</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Auriti</surname><given-names>C</given-names></name><name><surname>Prencipe</surname><given-names>G</given-names></name><name><surname>Moriondo</surname><given-names>M</given-names></name><name><surname>Bersani</surname><given-names>I</given-names></name><name><surname>Bertaina</surname><given-names>C</given-names></name><name><surname>Mondi</surname><given-names>V</given-names></name></person-group><article-title>Mannose-binding lectin: biologic characteristics and role in the susceptibility to infections and ischemia-reperfusion related injury in critically ill neonates</article-title><source>J Immunol Res</source><volume>2017</volume><year>2017</year><object-id pub-id-type="publisher-id">7045630</object-id></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Diebolder</surname><given-names>CA</given-names></name><name><surname>Beurskens</surname><given-names>FJ</given-names></name><name><surname>de Jong</surname><given-names>RN</given-names></name><name><surname>Koning</surname><given-names>RI</given-names></name><name><surname>Strumane</surname><given-names>K</given-names></name><name><surname>Lindorfer</surname><given-names>MA</given-names></name></person-group><article-title>Complement is activated by IgG hexamers assembled at the cell surface</article-title><source>Science</source><volume>343</volume><year>2014</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">24626930</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>S</given-names></name><name><surname>Gewurz</surname><given-names>H</given-names></name><name><surname>Mold</surname><given-names>C</given-names></name></person-group><article-title>Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis</article-title><source>J Immunol</source><volume>136</volume><year>1986</year><fpage>1354</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">3944459</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Biro</surname><given-names>A</given-names></name><name><surname>Rovo</surname><given-names>Z</given-names></name><name><surname>Papp</surname><given-names>D</given-names></name><name><surname>Cervenak</surname><given-names>L</given-names></name><name><surname>Varga</surname><given-names>L</given-names></name><name><surname>Fust</surname><given-names>G</given-names></name></person-group><article-title>Studies on the interactions between C-reactive protein and complement proteins</article-title><source>Immunology</source><volume>121</volume><year>2007</year><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17244159</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Braig</surname><given-names>D</given-names></name><name><surname>Nero</surname><given-names>TL</given-names></name><name><surname>Koch</surname><given-names>HG</given-names></name><name><surname>Kaiser</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Thiele</surname><given-names>JR</given-names></name></person-group><article-title>Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><object-id pub-id-type="publisher-id">14188</object-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Harboe</surname><given-names>M</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Karlstrom</surname><given-names>E</given-names></name><name><surname>Lindstad</surname><given-names>JK</given-names></name><name><surname>Stahl</surname><given-names>GL</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name></person-group><article-title>The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification</article-title><source>Mol Immunol</source><volume>47</volume><year>2009</year><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">19800125</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Harboe</surname><given-names>M</given-names></name><name><surname>Ulvund</surname><given-names>G</given-names></name><name><surname>Vien</surname><given-names>L</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name></person-group><article-title>The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation</article-title><source>Clin Exp Immunol</source><volume>138</volume><year>2004</year><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">15544620</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>CQ</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Ricklin</surname><given-names>D</given-names></name></person-group><article-title>Protection of host cells by complement regulators</article-title><source>Immunol Rev</source><volume>274</volume><year>2016</year><fpage>152</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">27782321</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Sanchez-Corral</surname><given-names>P</given-names></name><name><surname>Pouw</surname><given-names>RB</given-names></name><name><surname>Lopez-Trascasa</surname><given-names>M</given-names></name><name><surname>Jozsi</surname><given-names>M</given-names></name></person-group><article-title>Self-damage caused by dysregulation of the complement alternative pathway: relevance of the factor H protein family</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1607</fpage><pub-id pub-id-type="pmid">30050540</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Shanmugabhavananthan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Semple</surname><given-names>JW</given-names></name></person-group><article-title>C-reactive protein enhances murine antibody-mediated transfusion-related acute lung injury</article-title><source>Blood</source><volume>126</volume><year>2015</year><fpage>2747</fpage><lpage>2751</lpage><pub-id pub-id-type="pmid">26453659</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Rondina</surname><given-names>MT</given-names></name><name><surname>Porcelijn</surname><given-names>L</given-names></name><name><surname>Semple</surname><given-names>JW</given-names></name></person-group><article-title>Elevation of C-reactive protein levels in patients with transfusion-related acute lung injury</article-title><source>Oncotarget</source><volume>7</volume><year>2016</year><fpage>78048</fpage><lpage>78054</lpage><pub-id pub-id-type="pmid">27793007</pub-id></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Ambruso</surname><given-names>DR</given-names></name><name><surname>Silliman</surname><given-names>CC</given-names></name><name><surname>Kelher</surname><given-names>M</given-names></name><name><surname>Thurman</surname><given-names>G</given-names></name><name><surname>Giclas</surname><given-names>P</given-names></name></person-group><article-title>Complement activation in transfusion related acute lung injury (TRALI)</article-title><source>Blood (Abstract)</source><volume>954</volume><year>2006</year></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Palfi</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>S</given-names></name><name><surname>Ernerudh</surname><given-names>J</given-names></name><name><surname>Berlin</surname><given-names>G</given-names></name></person-group><article-title>A randomized controlled trial oftransfusion-related acute lung injury: is plasma from multiparous blood donors dangerous?</article-title><source>Transfusion</source><volume>41</volume><year>2001</year><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">11274583</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>G</given-names></name><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Hambley</surname><given-names>H</given-names></name><name><surname>Win</surname><given-names>N</given-names></name></person-group><article-title>Transfusion-related acute lung injury associated with interdonor incompatibility for the neutrophil-specific antigen HNA-1a</article-title><source>Vox Sang</source><volume>79</volume><year>2000</year><fpage>112</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">11054050</pub-id></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Dry</surname><given-names>SM</given-names></name><name><surname>Bechard</surname><given-names>KM</given-names></name><name><surname>Milford</surname><given-names>EL</given-names></name><name><surname>Churchill</surname><given-names>WH</given-names></name><name><surname>Benjamin</surname><given-names>RJ</given-names></name></person-group><article-title>The pathology of transfusion-related acute lung injury</article-title><source>Am J Clin Pathol</source><volume>112</volume><year>1999</year><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">10439802</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>GL</given-names></name><name><surname>McCarthy</surname><given-names>K</given-names></name><name><surname>Webster</surname><given-names>RO</given-names></name><name><surname>Henson</surname><given-names>J</given-names></name></person-group><article-title>Henson PM. A differential effect of C5a and C5a des Arg in the induction of pulmonary inflammation</article-title><source>Am J Pathol</source><volume>100</volume><year>1980</year><fpage>179</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">7395964</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>MC</given-names></name><name><surname>Stroo</surname><given-names>I</given-names></name><name><surname>Wouters</surname><given-names>D</given-names></name><name><surname>Zeerleder</surname><given-names>SS</given-names></name><name><surname>Roelofs</surname><given-names>JJ</given-names></name><name><surname>Boon</surname><given-names>L</given-names></name></person-group><article-title>The effect of C1-inhibitor in a murine model of transfusion-related acute lung injury</article-title><source>Vox Sang</source><volume>107</volume><year>2014</year><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">24372323</pub-id></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Strait</surname><given-names>RT</given-names></name><name><surname>Hicks</surname><given-names>W</given-names></name><name><surname>Barasa</surname><given-names>N</given-names></name><name><surname>Mahler</surname><given-names>A</given-names></name><name><surname>Khodoun</surname><given-names>M</given-names></name><name><surname>K&#x000f6;hl</surname><given-names>J</given-names></name></person-group><article-title>MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice</article-title><source>J Exp Med</source><volume>208</volume><year>2011</year><fpage>2525</fpage><lpage>2544</lpage><pub-id pub-id-type="pmid">22025304</pub-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>A</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>N</given-names></name></person-group><article-title>Sexual dimorphism of the fifth component of mouse complement</article-title><source>J Exp Med</source><volume>160</volume><year>1984</year><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">6470622</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Rebetz</surname><given-names>J</given-names></name><name><surname>Hallstr&#x000f6;m</surname><given-names>B</given-names></name><name><surname>Bj&#x000f6;rkman</surname><given-names>JT</given-names></name><name><surname>Takabe-French</surname><given-names>A</given-names></name></person-group><article-title>Gastrointestinal microbiota contributes to the development of murine transfusion-related acute lung injury</article-title><source>Blood Adv</source><volume>2</volume><year>2018</year><fpage>1651</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">29991496</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>UJ</given-names></name><name><surname>Hattar</surname><given-names>K</given-names></name><name><surname>Weissmann</surname><given-names>N</given-names></name><name><surname>Bohle</surname><given-names>RM</given-names></name><name><surname>Weiss</surname><given-names>T</given-names></name><name><surname>Sibelius</surname><given-names>U</given-names></name></person-group><article-title>Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model</article-title><source>Blood</source><volume>107</volume><year>2006</year><fpage>1217</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">16210340</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><mixed-citation publication-type="other" id="or0010">Seeger W, Schneider U, Kreusler B, von Witzleben E, Walmrath D, Grimminger F, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood 1990;76:1438-1444.</mixed-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Akerley</surname><given-names>WL</given-names><suffix>III</suffix></name><name><surname>Guyre</surname><given-names>PM</given-names></name><name><surname>Davis</surname><given-names>BH</given-names></name></person-group><article-title>Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties</article-title><source>Blood</source><volume>77</volume><year>1991</year><fpage>607</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">1703798</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Karsten</surname><given-names>CM</given-names></name><name><surname>Kohl</surname><given-names>J</given-names></name></person-group><article-title>The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases</article-title><source>Immunobiology</source><volume>217</volume><year>2012</year><fpage>1067</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">22964232</pub-id></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Kolaczkowska</surname><given-names>E</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><article-title>Neutrophil recruitment and function in health and inflammation</article-title><source>Nat Rev Immunol</source><volume>13</volume><year>2013</year><fpage>159</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">23435331</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Aleman</surname><given-names>OR</given-names></name><name><surname>Mora</surname><given-names>N</given-names></name><name><surname>Cortes-Vieyra</surname><given-names>R</given-names></name><name><surname>Uribe-Querol</surname><given-names>E</given-names></name><name><surname>Rosales</surname><given-names>C</given-names></name></person-group><article-title>Differential use of human neutrophil Fcgamma receptors for inducing neutrophil extracellular trap formation</article-title><source>J Immunol Res</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">2908034</object-id></element-citation></ref><ref id="bb0270"><label>54</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Nimmerjahn</surname><given-names>F</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name></person-group><article-title>Fcgamma receptors as regulators of immune responses</article-title><source>Nat Rev Immunol</source><volume>8</volume><year>2008</year><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">18064051</pub-id></element-citation></ref><ref id="bb0275"><label>55</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>J</given-names></name><name><surname>Nagelkerke</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Geissler</surname><given-names>J</given-names></name><name><surname>Rispens</surname><given-names>T</given-names></name><name><surname>van den Berg</surname><given-names>TK</given-names></name></person-group><article-title>Haplotypes of FcgammaRIIa and FcgammaRIIIb polymorphic variants influence IgG-mediated responses in neutrophils</article-title><source>J Immunol</source><volume>192</volume><year>2014</year><fpage>2715</fpage><lpage>2721</lpage><pub-id pub-id-type="pmid">24554771</pub-id></element-citation></ref><ref id="bb0280"><label>56</label><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>GT</given-names></name><name><surname>Green</surname><given-names>ER</given-names></name><name><surname>Mecsas</surname><given-names>J</given-names></name></person-group><article-title>Neutrophils to the ROScue: mechanisms of NADPH oxidase activation and bacterial resistance</article-title><source>Front Cell Infect Microbiol</source><volume>7</volume><year>2017</year><fpage>373</fpage><pub-id pub-id-type="pmid">28890882</pub-id></element-citation></ref><ref id="bb0285"><label>57</label><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Jakus</surname><given-names>Z</given-names></name><name><surname>Simon</surname><given-names>E</given-names></name><name><surname>Frommhold</surname><given-names>D</given-names></name><name><surname>Sperandio</surname><given-names>M</given-names></name><name><surname>Mocsai</surname><given-names>A</given-names></name></person-group><article-title>Critical role of phospholipase Cgamma2 in integrin and Fc receptor-mediated neutrophil functions and the effector phase of autoimmune arthritis</article-title><source>J Exp Med</source><volume>206</volume><year>2009</year><fpage>577</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">19273622</pub-id></element-citation></ref><ref id="bb0290"><label>58</label><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name><surname>Khameneh</surname><given-names>HJ</given-names></name><name><surname>Ho</surname><given-names>AW</given-names></name><name><surname>Laudisi</surname><given-names>F</given-names></name><name><surname>Derks</surname><given-names>H</given-names></name><name><surname>Kandasamy</surname><given-names>M</given-names></name><name><surname>Sivasankar</surname><given-names>B</given-names></name></person-group><article-title>C5a regulates IL-1beta production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis</article-title><source>Front Pharmacol</source><volume>8</volume><year>2017</year><fpage>10</fpage><pub-id pub-id-type="pmid">28167912</pub-id></element-citation></ref><ref id="bb0295"><label>59</label><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Jennette</surname><given-names>JC</given-names></name><name><surname>Schneider</surname><given-names>W</given-names></name><name><surname>Luft</surname><given-names>FC</given-names></name><name><surname>Kettritz</surname><given-names>R</given-names></name></person-group><article-title>C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis</article-title><source>J Am Soc Nephrol</source><volume>20</volume><year>2009</year><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">19073822</pub-id></element-citation></ref><ref id="bb0300"><label>60</label><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name><surname>Stoiber</surname><given-names>W</given-names></name><name><surname>Obermayer</surname><given-names>A</given-names></name><name><surname>Steinbacher</surname><given-names>P</given-names></name><name><surname>Krautgartner</surname><given-names>WD</given-names></name></person-group><article-title>The role of reactive oxygen species (ROS) in the formation of extracellular traps (ETs) in humans</article-title><source>Biomolecules</source><volume>5</volume><year>2015</year><fpage>702</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">25946076</pub-id></element-citation></ref><ref id="bb0305"><label>61</label><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Nishi</surname><given-names>H</given-names></name><name><surname>Travers</surname><given-names>R</given-names></name><name><surname>Tsuboi</surname><given-names>N</given-names></name><name><surname>Martinod</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>DD</given-names></name></person-group><article-title>Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo</article-title><source>Blood</source><volume>120</volume><year>2012</year><fpage>4421</fpage><lpage>4431</lpage><pub-id pub-id-type="pmid">22955924</pub-id></element-citation></ref><ref id="bb0310"><label>62</label><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Aleyd</surname><given-names>E</given-names></name><name><surname>Al</surname><given-names>M</given-names></name><name><surname>Tuk</surname><given-names>CW</given-names></name><name><surname>van der Laken</surname><given-names>CJ</given-names></name></person-group><article-title>van EM. IgA Complexes in plasma and synovial fluid of patients with rheumatoid arthritis induce neutrophil extracellular traps via FcalphaRI</article-title><source>J Immunol</source><volume>197</volume><year>2016</year><fpage>4552</fpage><lpage>4559</lpage><pub-id pub-id-type="pmid">27913645</pub-id></element-citation></ref><ref id="bb0315"><label>63</label><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Yipp</surname><given-names>BG</given-names></name><name><surname>Petri</surname><given-names>B</given-names></name><name><surname>Salina</surname><given-names>D</given-names></name><name><surname>Jenne</surname><given-names>CN</given-names></name><name><surname>Scott</surname><given-names>BN</given-names></name><name><surname>Zbytnuik</surname><given-names>LD</given-names></name></person-group><article-title>Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo</article-title><source>Nat Med</source><volume>18</volume><year>2012</year><fpage>1386</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">22922410</pub-id></element-citation></ref><ref id="bb0320"><label>64</label><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name><surname>Guglietta</surname><given-names>S</given-names></name><name><surname>Chiavelli</surname><given-names>A</given-names></name><name><surname>Zagato</surname><given-names>E</given-names></name><name><surname>Krieg</surname><given-names>C</given-names></name><name><surname>Gandini</surname><given-names>S</given-names></name><name><surname>Ravenda</surname><given-names>PS</given-names></name></person-group><article-title>Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis</article-title><source>Nat Commun</source><volume>7</volume><year>2016</year><object-id pub-id-type="publisher-id">11037</object-id></element-citation></ref><ref id="bb0325"><label>65</label><element-citation publication-type="journal" id="rf0315"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>LJ</given-names></name><name><surname>Damgaard</surname><given-names>C</given-names></name><name><surname>Holmstrup</surname><given-names>P</given-names></name><name><surname>Nielsen</surname><given-names>CH</given-names></name></person-group><article-title>Influence of complement on neutrophil extracellular trap release induced by bacteria</article-title><source>J Periodontal Res</source><volume>51</volume><year>2016</year><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">25900429</pub-id></element-citation></ref><ref id="bb0330"><label>66</label><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name><surname>Behnen</surname><given-names>M</given-names></name><name><surname>Leschczyk</surname><given-names>C</given-names></name><name><surname>Moller</surname><given-names>S</given-names></name><name><surname>Batel</surname><given-names>T</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Solbach</surname><given-names>W</given-names></name></person-group><article-title>Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcgammaRIIIB and Mac-1</article-title><source>J Immunol</source><volume>193</volume><year>2014</year><fpage>1954</fpage><lpage>1965</lpage><pub-id pub-id-type="pmid">25024378</pub-id></element-citation></ref><ref id="bb0335"><label>67</label><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Neutrophil extracellular traps can activate alternative complement pathways</article-title><source>Clin Exp Immunol</source><volume>181</volume><year>2015</year><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">25963026</pub-id></element-citation></ref><ref id="bb0340"><label>68</label><element-citation publication-type="journal" id="rf0330"><person-group person-group-type="author"><name><surname>Tsuboi</surname><given-names>N</given-names></name><name><surname>Ernandez</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Nishi</surname><given-names>H</given-names></name><name><surname>Cullere</surname><given-names>X</given-names></name><name><surname>Mekala</surname><given-names>D</given-names></name></person-group><article-title>Regulation of human neutrophil Fcgamma receptor IIa by C5a receptor promotes inflammatory arthritis in mice</article-title><source>Arthritis Rheum</source><volume>63</volume><year>2011</year><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">21280001</pub-id></element-citation></ref><ref id="bb0345"><label>69</label><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group><article-title>The role of C5a in acute lung injury induced by highly pathogenic viral infections</article-title><source>Emerg Microbes Infect</source><volume>4</volume><year>2015</year><fpage>e28</fpage><pub-id pub-id-type="pmid">26060601</pub-id></element-citation></ref><ref id="bb0350"><label>70</label><element-citation publication-type="journal" id="rf0340"><person-group person-group-type="author"><name><surname>van Riel</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>H5N1 virus attachment to lower respiratory tract</article-title><source>Science</source><volume>312</volume><year>2006</year><fpage>399</fpage><pub-id pub-id-type="pmid">16556800</pub-id></element-citation></ref><ref id="bb0355"><label>71</label><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>R</given-names></name><name><surname>Torii</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name></person-group><article-title>Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza</article-title><source>Microbiol Immunol</source><volume>55</volume><year>2011</year><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">21244468</pub-id></element-citation></ref><ref id="bb0360"><label>72</label><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>CC</given-names></name><name><surname>Weston-Davies</surname><given-names>W</given-names></name><name><surname>Russo</surname><given-names>RC</given-names></name><name><surname>Tavares</surname><given-names>LP</given-names></name><name><surname>Rachid</surname><given-names>MA</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name></person-group><article-title>Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e64443</object-id></element-citation></ref><ref id="bb0365"><label>73</label><element-citation publication-type="journal" id="rf0355"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection</article-title><source>Am J Respir Cell Mol Biol</source><volume>49</volume><year>2013</year><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">23526211</pub-id></element-citation></ref><ref id="bb0370"><label>74</label><element-citation publication-type="journal" id="rf0360"><person-group person-group-type="author"><name><surname>Russkamp</surname><given-names>NF</given-names></name><name><surname>Ruemmler</surname><given-names>R</given-names></name><name><surname>Roewe</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>BB</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name><name><surname>Bosmann</surname><given-names>M</given-names></name></person-group><article-title>Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin</article-title><source>FASEB J</source><volume>29</volume><year>2015</year><fpage>3762</fpage><lpage>3772</lpage><pub-id pub-id-type="pmid">25999468</pub-id></element-citation></ref><ref id="bb0375"><label>75</label><element-citation publication-type="journal" id="rf0365"><person-group person-group-type="author"><name><surname>Bosmann</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group><article-title>Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps</article-title><source>Expert Opin Ther Targets</source><volume>18</volume><year>2014</year><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">24670033</pub-id></element-citation></ref><ref id="bb0380"><label>76</label><element-citation publication-type="journal" id="rf0370"><person-group person-group-type="author"><name><surname>Morsing</surname><given-names>KSH</given-names></name><name><surname>Peters</surname><given-names>AL</given-names></name><name><surname>van Buul</surname><given-names>JD</given-names></name><name><surname>Vlaar</surname><given-names>APJ</given-names></name></person-group><article-title>The role of endothelium in the onset of antibody-mediated TRALI</article-title><source>Blood Rev</source><volume>32</volume><year>2018</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">28823763</pub-id></element-citation></ref><ref id="bb0385"><label>77</label><element-citation publication-type="journal" id="rf0375"><person-group person-group-type="author"><name><surname>Narasaraju</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>E</given-names></name><name><surname>Samy</surname><given-names>RP</given-names></name><name><surname>Ng</surname><given-names>HH</given-names></name><name><surname>Poh</surname><given-names>WP</given-names></name><name><surname>Liew</surname><given-names>AA</given-names></name></person-group><article-title>Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis</article-title><source>Am J Pathol</source><volume>179</volume><year>2011</year><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">21703402</pub-id></element-citation></ref><ref id="bb0390"><label>78</label><element-citation publication-type="journal" id="rf0380"><person-group person-group-type="author"><name><surname>Till</surname><given-names>GO</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group><article-title>Oxygen radicals in complement and neutrophil-mediated acute lung injury</article-title><source>J Free Radic Biol Med</source><volume>1</volume><year>1985</year><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">3915302</pub-id></element-citation></ref><ref id="bb0395"><label>79</label><element-citation publication-type="journal" id="rf0385"><person-group person-group-type="author"><name><surname>Lefrancais</surname><given-names>E</given-names></name><name><surname>Mallavia</surname><given-names>B</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Looney</surname><given-names>MR</given-names></name></person-group><article-title>Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury</article-title><source>JCI Insight</source><volume>3</volume><year>2018</year></element-citation></ref><ref id="bb0400"><label>80</label><element-citation publication-type="journal" id="rf0390"><person-group person-group-type="author"><name><surname>Zilow</surname><given-names>G</given-names></name><name><surname>Sturm</surname><given-names>JA</given-names></name><name><surname>Rother</surname><given-names>U</given-names></name><name><surname>Kirschfink</surname><given-names>M</given-names></name></person-group><article-title>Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome</article-title><source>Clin Exp Immunol</source><volume>79</volume><year>1990</year><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">2311295</pub-id></element-citation></ref><ref id="bb0405"><label>81</label><element-citation publication-type="journal" id="rf0395"><person-group person-group-type="author"><name><surname>Hammerschmidt</surname><given-names>DE</given-names></name><name><surname>Weaver</surname><given-names>LJ</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name><name><surname>Craddock</surname><given-names>PR</given-names></name><name><surname>Jacob</surname><given-names>HS</given-names></name></person-group><article-title>Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value</article-title><source>Lancet</source><volume>1</volume><year>1980</year><fpage>947</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">6103300</pub-id></element-citation></ref><ref id="bb0410"><label>82</label><element-citation publication-type="journal" id="rf0400"><person-group person-group-type="author"><name><surname>Schein</surname><given-names>RM</given-names></name><name><surname>Bergman</surname><given-names>R</given-names></name><name><surname>Marcial</surname><given-names>EH</given-names></name><name><surname>Schultz</surname><given-names>D</given-names></name><name><surname>Duncan</surname><given-names>RC</given-names></name><name><surname>Arnold</surname><given-names>PI</given-names></name></person-group><article-title>Complement activation and corticosteroid therapy in the development of the adult respiratory distress syndrome</article-title><source>Chest</source><volume>91</volume><year>1987</year><fpage>850</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">3556054</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0035"><title>Acknowledgments</title><p id="p0115">This work was supported by <funding-source id="gts0005">Sanquin</funding-source> (grant PPOC-18-08).</p></sec><sec id="s0040"><title>Declaration of Competing Interest</title><p id="p0120">None.</p></sec></ack></back></article>